AØAnne Ahrens Østergaard

Anne Ahrens Østergaard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anne Ahrens Østergaard has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diagnostic performance of circulating microRNA signatures for differentiating tuberculosis disease from tuberculosis infection

    by Anne Ahrens Østergaard, Stephanie Bjerrum, Kristian Assing, Maria Bisgaard Borup, Rasmus Bank Lynggaard, Christiane Abildgaard, Ingrid Louise Titlestad, Torben Tranborg Jensen, Hans Johan Niklas Lorentsson, Ole Hilberg, et al.

    As regulators of innate and adaptive immunity, microRNAs (miRNAs) could aid in the discrimination between tuberculosis disease (TB) and (latent) TB infection (TBI). We analysed 754 circulating miRNAs in participants diagnosed with TB and TBI using TaqMan™ Advanced miRNA Human A and B cards. MiRNAs were normalized exogenously and endogenously via geometric means of selected reference miRNAs. Expression analysis was used to identify miRNAs that were significantly differentially expressed between individuals with TB and those with TBI. We utilised recursive feature elimination with a Random Forest model to identify the miRNAs most effective at discriminating TB from TBI and subsequently validated the miRNA in another group. 95 persons diagnosed with TB or TBI was divided into a discovery group (n = 36) and a validation group (n = 59). In the discovery group, we identified 495 distinct miRNAs in 36 persons with TB or TBI and by recursive feature elimination identified hsa-miR-148a-3p, hsa-miR-204-5p and hsa-miR-584-5p and created a three-miRNA-diagnostic model. In the validation group, the three-miRNA-diagnostic model had poorer performance. Expression analysis revealed 13 significantly differentially expressed miRNAs, including hsa-miR-148a-3p and hsa-miR-204-5p. Subsequent analysis in a validation group consisting of 59 persons revealed that six of the 14 miRNAs, including hsa-miR-148a-3p, exhibited the same pattern, albeit without statistical significance. Three circulating miRNAs showed potential for differentiating TB from TBI in the discovery cohort, but these differences were less pronounced in the validation cohort.


  • Open Access

    Risk of serious bacterial infections in inflammatory rheumatic or bowel disease patients during biological therapies: nationwide Danish cohort study

    by Emma Cathrine Højberg Platz, Gustav Emil Laugesen, Anne Ahrens Østergaard, Keld-Erik Byg, Inge Petersen, Isik Somuncu Johansen

    To estimate the incidence rate ratio (IRR) of serious bacterial infections (SI) in patients with inflammatory bowel disease (IBD) or inflammatory rheumatic disease (IRD) before and after initiating biological therapy, and to assess comorbidities, infection sites, and the type of biological therapy. This nationwide retrospective registry-based study used a cohort-crossover design to assess the relative risk of SI one year before and after treatment. Data from the Danish National Patient Registry included 20,216 patients with IBD or IRD. Diagnosis codes for hospital contacts (inpatients, outpatients, day patients, and emergency department patients) and hospital-treated bacterial infections from 1994 to 2018 were linked using the Civil Registration System. There were 1235 infections during 19,529 person-years one year before treatment, compared to 1251 infections over 17,831 person-years one year after treatment initiation (IRR = 1.11, 95% CI [1.03-1.19], p = 0.01). The incidence rate was 2-fold higher in the first three months post-treatment compared to over one year. Increased risks were found for bacterial infections without specified site; ear, nose, and throat; and respiratory tract infections. Higher risks of SI after treatment initiation were associated with comorbidities, treatment initiation between 2015 and 2018, age ≥61 at inflammatory disease diagnosis [HR = 1.50 (1.31-1.72)], female sex, and corticosteroid co-administration. Anakinra showed a significantly increased risk of infection [HR = 2.02, 95%CI 1.03-3.97)] in IRD patients. We found a modestly increased risk of SI in the year following therapy initiation, with the highest risk in the first three months. This risk was associated with certain baseline factors, highlighting the need for thorough risk assessment when starting treatment.


  • Open Access

    Whole-blood culture-derived cytokine combinations for the diagnosis of tuberculosis

    by Anne Ahrens Østergaard, Søren Feddersen, Mike B. Barnkob, Rasmus Bank Lynggaard, Amanda Cecilie Annie Karstoft, Maria Borup, Ingrid Louise Titlestad, Torben Tranborg Jensen, Ole Hilberg, Christian Wejse, et al.

    Introduction: The diagnosis of tuberculosis (TB) disease and TB infection (TBI) remains a challenge, and there is a need for non-invasive and blood-based methods to differentiate TB from conditions mimicking TB (CMTB), TBI, and healthy controls (HC). We aimed to determine whether combination of cytokines and established biomarkers could discriminate between 1) TB and CMTB 2) TB and TBI 3) TBI and HC. Methods: We used hemoglobin, total white blood cell count, neutrophils, monocytes, C-reactive protein, and ten Meso Scale Discovery analyzed cytokines (interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, interferon (IFN)-ɣ, and tumor necrosis factor (TNF)-α) in TruCulture whole blood tubes stimulated by lipopolysaccharides (LPS), zymosan (ZYM), anti-CD3/28 (CD3), and unstimulated (Null) to develop three index tests able to differentiate TB from CMTB and TBI, and TBI from HC. Results: In 52 persons with CMTB (n=9), TB (n=23), TBI (n=10), and HC (n=10), a combination of cytokines (LPS-IFN-ɣ, ZYM-IFN-ɣ, ZYM-TNF-α, ZYM-IL-1β, LPS-IL-4, and ZYM-IL-6) and neutrophil count could differentiate TB from CMTB with a sensitivity of 52.2% (95% CI: 30.9%–73.4%) and a specificity of 100 % (66.4%-100%). Null- IFN-ɣ, Null-IL-8, CD3-IL-6, CD3-IL-8, CD3-IL-13, and ZYM IL-1b discriminated TB from TBI with a sensitivity of 73.9% (56.5% - 91.3%) and a specificity of 100% (69.2-100). Cytokines and established biomarkers failed to differentiate TBI from HC with ≥ 98% specificity.Discussion: Selected cytokines may serve as blood-based add-on tests to detect TB in a low-endemic setting, although these results need to be validated.


  • Open Access

    Prevalence estimates of tuberculosis infection in adults in Denmark: a retrospective nationwide register-based cross-sectional study, 2010 to 2018

    by Anne Ahrens Østergaard, Troels Lillebaek, Inge Petersen, Andreas Fløe, Eliza H Worren Bøkan, Ole Hilberg, Inge K Holden, Lone Larsen, Ada Colic, Christian Wejse, et al.

    Background: Tuberculosis (TB) elimination requires identifying and treating persons with TB infection (TBI). Aim: We estimate the prevalence of positive interferon gamma release assay (IGRA) tests (including TB) and TBI (excluding TB) in Denmark based on TBI screening data from patients with inflammatory bowel disease (IBD) or inflammatory rheumatic disease (IRD). Methods: Using nationwide Danish registries, we included all patients with IBD or IRD with an IGRA test performed between 2010 and 2018. We estimated the prevalence of TBI and positive IGRA with 95% confidence intervals (CI) in adolescents and adults aged 15–64 years after sample weighting adjusting for distortions in the sample from the background population of Denmark for sex, age group and TB incidence rates (IR) in country of birth. Results: In 13,574 patients with IBD or IRD, 12,892 IGRA tests (95.0%) were negative, 461 (3.4%) were positive and 221 (1.6%) were indeterminate, resulting in a weighted TBI prevalence of 3.2% (95% CI: 2.9–3.5) and weighted positive IGRA prevalence of 3.8% (95% CI: 3.5–4.2) among adults aged 15–64 years in the background population of Denmark. Unweighted TBI prevalence increased with age and birthplace in countries with a TB IR higher than 10/100,000 population. Conclusion: Estimated TBI prevalence is low in Denmark. We estimate that 200,000 persons have TBI and thus are at risk of developing TB. Screening for TBI and preventive treatment, especially in persons born in high TB incidence countries or immunosuppressed, are crucial to reduce the risk of and eliminate TB.


  • Open Access

    Cerebrospinal fluid pleocytosis level as a diagnostic predictor? A cross-sectional study

    by Anne Ahrens Østergaard, Thomas Vognbjerg Sydenham, Mads Nybo, Åse Bengård Andersen

    Lumbar puncture with quantification of leukocytes and differential count of cellular subsets in the cerebrospinal fluid is a standard procedure in cases of suspected neuroinfectious conditions. However, a number of non-infectious causes may result in a low leukocyte number (0–1000 cells/ml). We wanted to assess the diagnostic diversity of unselected adult patients with pleocytosis in the cerebrospinal fluid. The study is based on data from cerebrospinal fluid (CSF) analyses of all adult patients (15 years or older) admitted to a large university hospital in Denmark during a two-year period (2008–2009). Data from the local patient administrative system supplied with data from patient charts were combined with laboratory data. A total of 5390 cerebrospinal fluid samples from 3290 patients were included. Pleocytosis >5 leucocytes/μl was found in samples from 262 patients of which 106 (40.5%) were caused by infection of the central nervous system (CNS), 20 (7.6%) by infection outside CNS, 79 (30.2%) due to non-infectious neurological diseases, 23 (8.8%) by malignancy, and 34 (13.0%) caused by other conditions. Significantly higher mean CSF leukocytes was found in patients suffering from CNS infection (mean 1135 cells/μl, p-value <0.0001). CNS infection, non-infectious neurological disease, malignancy, and infection outside CNS can cause pleocytosis of the cerebrospinal fluid. Leukocyte counts above 100/μl is mainly caused by CNS infection, whereas the number of differential diagnoses is higher if the CSF leukocyte counts is below 50/μl. These conditions are most commonly caused by non-infectious neurological diseases including seizures.